The CUI was applied to data in a 12-week , open-label , Phase 2 trial in patients with type 2 diabetes mellitus who were randomized to one of two dosing algorithms for LY2605541 ( LY1 or LY2 ) or GL ( algorithm similar to LY1 ) .